MiLI: Mifepristone for Labor Induction

Sponsor
Stanford University (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT05097326
Collaborator
(none)
30
1
2
17.1
1.7

Study Details

Study Description

Brief Summary

The purpose of this trial is to explore mifepristone as an option for induction of labor at term by evaluating the efficacy of mifepristone use for cervical preparation. Since the Labor Induction versus Expectant Management in Low-Risk Nulliparous Women (ARRIVE) trial supporting that elective induction after 39 weeks decreases cesarean sections and morbidity, rates of elective term inductions are increasing.

At Lucile Packard Children's Hospital at Stanford University specifically, approximately 40% of spontaneous vaginal deliveries follow induction of labor, with an average induction time of 20 hours. Previous studies have established the maternal and neonatal safety of mifepristone in term inductions, however, this study will assess the difference in overall time from induction to complete cervical dilation, delivery, and the total time on Labor and Delivery.

Condition or Disease Intervention/Treatment Phase
Phase 3

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Mifepristone as an Adjunct to Transcervical Balloon for Labor Induction (MiLI): A Randomized Clinical Trial
Actual Study Start Date :
Jun 27, 2022
Anticipated Primary Completion Date :
Jun 1, 2023
Anticipated Study Completion Date :
Dec 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Mifepristone

Participants will be given mifepristone with insertion of the cervical Cook balloon for labor induction

Drug: Mifepristone
Mifepristone 200mg taken orally

Active Comparator: Misoprostol

Participants will be given misoprostol with insertion of the cervical Cook balloon for labor induction

Drug: Misoprostol
Misoprostol 50 mcg taken orally, and may receive additional doses of misoprostol 50 - 100 mcg as needed

Outcome Measures

Primary Outcome Measures

  1. Number of uterine contractions from time of medication administration to removal of the transcervical balloon [Up to approximately 72 hours after administration of the study medication]

    Measured total number of uterine contractions per hour - with and without fetal heart rate decelerations from time of medication administration to removal of transcervical balloon

  2. Measured number of total minutes of uterine tachysystole or hypertonus per hour from the time of medication administration until the time of delivery [Up to approximately 72 hours after administration of study medication]

    Measured number of total minutes of uterine tachysystole (more than 5 contractions in 10 minutes with and without fetal heart rate decelerations) or hypertonus (a single contraction lasting more than 2 minutes) per hour from the time of medication administration until the time of delivery

  3. Time from study medication administration to complete cervical dilation [Up to approximately 72 hours after the study medication administration]

    Total time from medication administration to complete cervical dilation (10 cms)

  4. Time from study medication administration to delivery [Up to approximately 72 hours after the study medication has been administered]

  5. Total Labor and Delivery unit admission duration time [Up to approximately 80 hours after the time of Labor and delivery admission]

    Total time on Labor & Delivery from the time of admission to the time of transfer to postpartum unit

  6. Number of patients who undergo cesarean delivery [Up to approximately 72 hours after the start of labor induction]

  7. Number of patients able to achieve active labor (6 cm) [Up to approximately 72 hours after the start of labor induction]

  8. Number of patients with severe maternal morbidity [Up to approximately 1 week after hospital admission for delivery]

    Number of participants with serious maternal morbidity or death based on CDC criteria for major maternal morbidity and mortality

  9. Mean neonatal arterial cord blood pH [Within approximately 2 hours after delivery (approximately 5 minutes to obtain sample)]

    Laboratory values for neonatal arterial cord blood pH

  10. Mean neonatal APGAR scores from 0-10 [At 1 minute and 5 minutes of infant life (approximately 10 seconds to perform each assessment)]

    Compare the APGAR scores (at 1 and 5 minutes). The Apgar score comprises five components: 1) color, 2) heart rate, 3) reflexes, 4) muscle tone, and 5) respiration, each of which is given a score of 0, 1, or 2. The score is reported at 1 minute and 5 minutes after birth for all infants,

  11. Number of patients with serious neonatal morbidity [Up to 7 days after birth]

    Defined as need for respiratory support within 72 hours after birth, hypoxic-ischemic encephalopathy, seizure, infection, meconium aspiration syndrome, intracranial or subgaleal hemorrhage, hypotension requiring vasopressor support, admission to neonatal intensive care unit

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 45 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Pregnant patients between ages 18 to 45 years

  2. Singleton, live gestation

  3. Nulliparous

  4. Gestational age between 37 weeks 0 days - 42 weeks 0 days

  5. Fetus in cephalic presentation

  6. Patients admitted for labor induction

  7. Patients who are not in labor with intact membranes

  8. Patients with no contraindication for vaginal delivery (placenta previa, vasa previa, active genital herpes)

  9. Patients with no contraindications for mifepristone (chronic adrenal failure, concurrent long-term corticosteroid therapy, history of allergy to mifepristone, or other prostaglandins, hemorrhagic disorders or concurrent anticoagulant therapy, inherited porphyria, or an intrauterine device (IUD) in place)

  10. Patients with a Bishop score <6 at time of randomization

  11. Transcervical balloon in place <3 hours prior to the time of randomization without prior cervical preparation

Exclusion Criteria:
  1. Significant cardiac, renal, or hepatic maternal comorbidities, severe gestational hypertension or preeclampsia with severe features

  2. Pregnancies complicated by major fetal anomalies

  3. Patients with a uterine scar

  4. Pregnancies complicated by fetal growth restriction (Estimated fetal weight <10%)

  5. Pregnancies complicated by oligohydramnios

  6. Fetuses with an estimated fetal weight >4500 gm by recent ultrasound or Leopold's exam on admission

  7. Patients with class 3 obesity (BMI >40)

  8. Fetuses with a persistent category 2 or 3 fetal heart tracing at labor induction admission

  9. Vaginal bleeding at the time of randomization

  10. Any indication for scheduled cesarean delivery

  11. Hypersensitivity to oxytocin

  12. Uterine contractions equal to or greater than 5 in 10 minutes for sustained 30 minutes

  13. Hypersensitivity to prostaglandins

Contacts and Locations

Locations

Site City State Country Postal Code
1 Lucile Packard Children's Hospital Palo Alto California United States 94304

Sponsors and Collaborators

  • Stanford University

Investigators

  • Principal Investigator: Kate Shaw, MD, Stanford University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Kate Ayers Shaw, Clinical Associate Professor, Stanford University
ClinicalTrials.gov Identifier:
NCT05097326
Other Study ID Numbers:
  • 62448
First Posted:
Oct 28, 2021
Last Update Posted:
Jul 1, 2022
Last Verified:
Jun 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 1, 2022